Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...

A mountain biker in his late 50s successfully overcame atrial fibrillation using a new heart procedure called pulse field ablation, as doctors report rising cases of the irregular heartbeat condition ...

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

In April, we reported on a study that raised alarms for safety issues with pulsed field ablation for atrial fibrillation. In this report, we follow up on subsequent developments for this technology.

Pulsed-field ablation (PFA) with a system encompassing the Varipulse catheter and Trupulse generator with integrated 3D electroanatomic mapping (all Biosense Webster) safely and effectively treats ...

Six-month outcomes from the Ventricular Catheter Ablation Study, the first-in-human evaluation of its FieldForce Ablation System for ventricular tachycardia (VT), have been published in Circulation.

Pulsed field ablation (PFA) proved a better first-line treatment for persistent atrial fibrillation (AF) than did antiarrhythmic drug therapy, with less recurrence and similar adverse event risk, the ...

VIENNA, Austria—For patients with paroxysmal atrial fibrillation (AF), pulsed-field ablation with the Farapulse system (Boston Scientific) is as good as—and borderline better than—a cryoballoon for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...